๐‚๐š๐ฌ-๐‚๐‹๐Ž๐•๐„๐‘ ๐ข๐ฌ ๐ฆ๐จ๐ซ๐ž ๐ญ๐ก๐š๐ง ๐ ๐ž๐ง๐ž ๐ž๐๐ข๐ญ๐ข๐ง๐ , ๐ข๐ญโ€™๐ฌ ๐š ๐›๐ฎ๐ฌ๐ข๐ง๐ž๐ฌ๐ฌ ๐š๐๐ฏ๐š๐ง๐ญ๐š๐ ๐ž.
At BioProcess International Fall Digital Week 2025, Demeetra presented: โ€œ๐‘ผ๐’๐’๐’๐’„๐’Œ๐’Š๐’๐’ˆ ๐’•๐’‰๐’† ๐‘ญ๐’–๐’•๐’–๐’“๐’† ๐’๐’‡ ๐‘ฉ๐’Š๐’๐’๐’๐’ˆ๐’Š๐’„๐’” ๐‘ด๐’‚๐’๐’–๐’‡๐’‚๐’„๐’•๐’–๐’“๐’Š๐’๐’ˆ: ๐‘ช๐’‚๐’”-๐‘ช๐‘ณ๐‘ถ๐‘ฝ๐‘ฌ๐‘น ๐’‡๐’๐’“ ๐‘ฉ๐’Š๐’ˆ ๐‘ท๐’‰๐’‚๐’“๐’Ž๐’‚ & ๐‘จ๐’…๐’—๐’‚๐’๐’„๐’†๐’… ๐‘ท๐’Š๐’‘๐’†๐’๐’Š๐’๐’†๐’”.โ€
Jack Crawford, CEO, outlines how Cas-CLOVER tackles two challenges facing Big Pharma today: securing robust commercial FTO and achieving scalable, high-efficiency performance beyond CRISPR and ZFNs. Then Corey Brizzee, PhD Brizzee, Ph.D., shares data-driven results on host cell optimization and multiplexed HCP removalโ€”showing how Cas-CLOVER is transforming cell line development from R&D to GMP scale. With flexible, milestone-free licensing, Cas-CLOVER helps biopharma teams accelerate innovation and ROI.

Access the full webcast recording here to watch on demand.

Build production-ready CHO cell lines with Demeetra

Talk to our team about CHO cell line development, or explore licensing and product access – including Super piggyBac.

Talk to an Expert
Explore Licensing Options